Tibolone
Intervention3 papers4 findingsPubChem 444008ChEBI 32223MeSH C027385
- Human trial1
- Humans2
Outcomes
2Lipid peroxidation
downin humans1Low certainty
1 study
Lipid peroxidation
downin humans1Low certainty
Tibolone decreases lipid peroxidation in humans.
Human trialpostmenopausal2.5 mg/day12 monthsfemales
Cortical and trabecular bone changes associated with tibolone in postmenopausal women: A randomized, open-label study compared with estrogen therapy and placebo · Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry · 22 Aug 2026
Bone mineral density
no changein humans1Low certainty
1 study
Bone mineral density
no changein humans1Low certainty
Tibolone has no effect on bone mineral density in humans.
Human trialpostmenopausal2.5 mg/day12 monthsfemales
Cortical and trabecular bone changes associated with tibolone in postmenopausal women: A randomized, open-label study compared with estrogen therapy and placebo · Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry · 22 Aug 2026
Associations
2Hepatocellular carcinoma
upin humans1HR 1.88Low certainty
1 study
Hepatocellular carcinoma
upin humans1HR 1.88Low certainty
Tibolone raises the risk of hepatocellular carcinoma in humans (HR 1.88, 95% CI 1.07-3.29).
Humans≥ 180 cumulative days of usemedian 11-year follow-upfemales
Tibolone Use Associated With Elevated Hepatocellular Carcinoma Risk: Findings From a Nationwide Cohort · International journal of cancer · 1 Sep 2026
Bladder cancer
downin humans1HR 0.69Low certainty
1 study
Bladder cancer
downin humans1HR 0.69Low certainty
Tibolone lowers the risk of bladder cancer in humans (HR 0.69, 95% CI 0.548-0.858).
Humanspostmenopausal womenfemales
Association Between Menopausal Hormone Therapy and the Risk of Urologic Cancer: A National Population-Based Retrospective Cohort Study in Korea · Journal of Korean medical science · 31 Aug 2026